TNNI3K Activators
TNNI3K Activators consist of various compounds that indirectly enhance the functional activity of TNNI3K, an important kinase involved in cardiac muscle function and response to stress. Bisindolylmaleimide I, as a PKC inhibitor, alters cardiac signaling pathways, potentially amplifying TNNI3K's involvement in myocardial function and stress response. Similarly, KN-93, by inhibiting CaMKII, affects calcium handling and myocardial contractility, key processes where TNNI3K plays a role. SB203580 and U0126, targeting p38 MAPK and MEK respectively, modulate signaling pathways related to cardiac hypertrophy and remodeling, a domain of TNNI3K activity. LY294002 and Wortmannin, both PI3K inhibitors, contribute to this modulation by impacting pathways involved in cardiac hypertrophy, potentially enhancing TNNI3K's function in these processes.
Further, Rapamycin, an mTOR inhibitor, affects cardiac hypertrophy and stress responses, pathways where TNNI3K is crucial, thus potentially augmenting its activity. AICAR and Metformin, both AMPK activators, influence myocardial energy metabolism and hypertrophic responses, integral to TNNI3K's role in the heart. Sildenafil and Dipyridamole, by inhibiting PDE5 and other phosphodiesterases respectively, alter myocardial contractility and response to stress through changes in cGMP and cAMP levels, thereby enhancing TNNI3K's function. Captopril, an ACE inhibitor, modulates the renin-angiotensin system, impacting cardiac remodeling and hypertrophy, processes in which TNNI3K is implicated. Collectively, these TNNI3K Activators, through their varied effects on kinase activity, signaling pathways, and metabolic regulation, enhance TNNI3K's crucial role in regulating cardiac function, particularly under conditions of stress and in processes like hypertrophy and remodeling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I, a PKC inhibitor, indirectly enhances TNNI3K activity by inhibiting protein kinase C. This inhibition can lead to altered cardiac signaling pathways, potentially increasing TNNI3K's role in cardiac muscle function and response to stress. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93, a Ca2+/calmodulin-dependent kinase II (CaMKII) inhibitor, indirectly enhances TNNI3K activity by modulating CaMKII signaling. This can lead to changes in calcium handling and myocardial contractility, where TNNI3K is involved. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly enhances TNNI3K function by inhibiting p38 MAPK. This alteration in signaling pathways can affect cardiac hypertrophy and stress responses, potentially enhancing TNNI3K's role in these processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly enhances TNNI3K function by reducing PI3K activity. This can influence cardiac hypertrophy and myocardial contractility, potentially augmenting TNNI3K's role in these processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly enhances TNNI3K activity by inhibiting the mTOR pathway, which is involved in cardiac hypertrophy and response to stress. This inhibition can affect TNNI3K's role in these processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, another PI3K inhibitor, indirectly enhances TNNI3K activity by inhibiting PI3K. This can lead to alterations in cardiac hypertrophy and function, where TNNI3K plays a significant role. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR, an AMPK activator, indirectly enhances TNNI3K activity by activating AMPK. This can influence myocardial energy metabolism and stress responses, potentially enhancing TNNI3K's role in these processes. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin, an AMPK activator, indirectly enhances TNNI3K function by activating AMPK, leading to changes in cardiac energy metabolism and hypertrophic responses where TNNI3K is involved. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole, another PDE inhibitor, indirectly enhances TNNI3K activity by increasing cAMP and cGMP levels, which can influence myocardial contractility and response to cardiac stress, potentially enhancing TNNI3K's role. | ||||||
Captopril | 62571-86-2 | sc-200566 sc-200566A | 1 g 5 g | $49.00 $91.00 | 21 | |
Captopril, an ACE inhibitor, indirectly enhances TNNI3K activity by modulating the renin-angiotensin system, affecting cardiac hypertrophy and remodeling, where TNNI3K is involved. | ||||||